Product image of Methotrexaat Accord (Methotrexate) supplied by GNH India

Methotrexaat Accord

Active Ingredient:
Methotrexate
Origin:
EU

Methotrexaat Accord (Methotrexate)

Methotrexate, the active ingredient in Methotrexaat Accord, is an antimetabolite (folate antagonist) presented as an oral tablet for oral use. It is employed to manage autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as specific cancers including acute lymphoblastic leukemia, non‑Hodgkin lymphoma and breast cancer, in adult patients.

GNH India supplies Methotrexaat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets and ensuring quality and regulatory compliance.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexaat Accord (methotrexate) is used across several disease families where folate metabolism is a therapeutic target.

  • Rheumatoid arthritis: reduces joint inflammation and slows disease progression.
  • Psoriasis: decreases skin cell proliferation and improves plaque severity.
  • Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission.
  • Non‑Hodgkin lymphoma: impedes tumor growth as part of combination chemotherapy.
  • Breast cancer: used in adjuvant regimens to limit tumor recurrence.
  • Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

How It Works

  • Methotrexate competitively inhibits dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate. This blockade reduces the cellular pool of tetrahydrofolate needed for synthesis of purine nucleotides and thymidylate, thereby impairing DNA, RNA and protein synthesis. The resulting antiproliferative effect is most pronounced in rapidly dividing cells, including activated immune cells and malignant tumor cells.

Side Effects

Methotrexaat Accord may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Fatigue: general tiredness or weakness.
  • Mouth sores: inflammation of oral mucosa.
  • Elevated liver enzymes: mild hepatic irritation.
  • Low blood counts: mild leukopenia or anemia.
  • Hair thinning: temporary reduction in hair growth.

Serious or Rare Side Effects

  • Severe liver toxicity: potential for hepatitis or fibrosis.
  • Pulmonary fibrosis: progressive lung scarring.
  • Bone marrow failure: pancytopenia requiring medical intervention.
  • Renal impairment: acute kidney injury.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

When prescribing Methotrexaat Accord, clinicians should observe several safety measures to minimize risk.

  • Pregnancy contraindication: avoid use in pregnancy (Category X) due to teratogenic risk.
  • Renal function monitoring: assess creatinine clearance before and during therapy.
  • Hepatic monitoring: perform baseline and periodic liver function tests.
  • Hematologic surveillance: monitor complete blood count regularly.
  • Drug interactions: review concomitant medications for potential synergistic toxicity.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Avoid Interactions

Methotrexaat Accord interacts with several agents that can alter its efficacy or toxicity.

Major Interactions (Avoid)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity.
  • Proton pump inhibitors: may raise methotrexate plasma levels.
  • Trimethoprim‑sulfamethoxazole: enhances hematologic toxicity.

Moderate Interactions (Monitor Closely)

  • Penicillins (e.g., ampicillin): can reduce renal clearance of methotrexate.
  • Sulfonamides: may increase risk of bone marrow suppression.
  • Live vaccines: immunosuppression may diminish vaccine efficacy.

Frequently Asked Questions

Methotrexaat Accord contains methotrexate and is indicated for rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, breast cancer, and ectopic pregnancy, where it helps control disease activity or eradicate abnormal cells.

Methotrexate blocks the enzyme dihydrofolate reductase, stopping the formation of tetrahydrofolate. This limits the synthesis of DNA, RNA and proteins, which reduces the proliferation of immune cells and cancer cells that rely on rapid growth.

The dosage of Methotrexaat Accord is determined by the prescribing clinician based on the specific indication, patient characteristics and treatment goals. Only a qualified health professional should set the dose and schedule.

Methotrexaat Accord is classified as Pregnancy Category X because it is known to cause fetal harm. It should not be used by pregnant women, and breastfeeding is contraindicated due to the risk of drug transfer to the infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methotrexaat Accord (methotrexate) is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase. Methotrexate’s broad activity across autoimmune and oncologic indications makes it a versatile option, but its safety profile requires careful monitoring compared with agents that have different toxicity patterns.

Methotrexaat Accord should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and sources of heat to maintain stability.

Methotrexaat Accord is taken orally as a tablet. The patient swallows the tablet whole with water, usually on an empty stomach or as directed by the prescriber, and follows any additional instructions regarding timing relative to meals or other medications.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone marrow failure leading to pancytopenia, renal impairment, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms develop.

Methotrexaat Accord should not be used by pregnant or breastfeeding individuals, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate, or anyone taking contraindicated medications without appropriate medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT